Skip to main content
SpringerLink
Log in

A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    Article  CAS  Google Scholar 

  2. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M . New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005; 90: 534–541.

    CAS  PubMed  Google Scholar 

  3. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.

    Article  CAS  Google Scholar 

  4. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  Google Scholar 

  5. Gruber FX, Lamark T, Anonli A, Sovershaev MA, Olsen M, Gedde-Dahl T et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005; 19: 2159–2165.

    Article  CAS  Google Scholar 

  6. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.

    Article  CAS  Google Scholar 

  7. Nalla VK, Rogan PK . Automated splicing mutation analysis by information theory. Hum Mutat 2005; 25: 334–342.

    Article  CAS  Google Scholar 

  8. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938–1942.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Per Arne Standal for providing patient samples and Mikhail Sovershaev for support in graphical design. This study was supported by a grant given by the Northern Norwegian Health Authorities (SFP 54-06).

Author information

Authors and Affiliations

  1. Department of Pharmacology, Institute of Pharmacy, University of Tromsø, Tromsø, Norway

    F X Gruber & I Mikkola

  2. Department of Hematology, St Olavs Hospital, Trondheim, Norway

    H Hjorth-Hansen

  3. Hematology Centre, Karolinska University Hospital and Institute, Stockholm, Sweden

    L Stenke

  4. Department of Biochemistry, Institute of Medical Biology, University of Tromsø, Tromsø, Norway

    T Johansen

Authors
  1. F X Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Hjorth-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Mikkola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Stenke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Johansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gruber, F., Hjorth-Hansen, H., Mikkola, I. et al. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia 20, 2057–2060 (2006). https://doi.org/10.1038/sj.leu.2404400

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404400

  • Springer Nature Limited

This article is cited by

Search

Navigation